ABSTRACT Objective: In metastatic gastric cancer (MGC), the goals of treatment are palliation and prolongation of overall survival (OS). Systemic chemotherapy, with docetaxel, cisplatin, infusional 5-fluorouracil (DCF) the most preferred regimen, is the mainstay of the treatment. We evaluated the efficacy and tolerability of weekly DCF (wDCF) compared to standard DCF regimen. Methods: We retrospectively reviewed 49 and 32 MGC patients treated with DCF and wDCF regimens as first-line treatment, respectively. The wDCF protocol included 25 mg/m2 docetaxel, 25 mg/m2 cisplatin and 750 mg/m2 infusional 5-FU on day 1, every week. Each cycle was repeated every 3 weeks. Results: The patients in wDCF arm were significantly older (median 54 vs 72.5) and had poor Eastern Cooperative Oncology Group performance status (ECOG PS) than patients in DCF arm (p < 0.001). Progression-free survival was 3 vs 5 months (p=0.75) and OS was 7 vs 9 months in wDCF and DCF arms (p=0.33), respectively. Overall response rate was observed in 28.5 and 31.2% of the patients in DCF and wDCF arms, respectively (p = 0.65). Haematologic toxicides were observed more common in wDCF arm. Conclusion: Weekly DCF is an effective and tolerable regimen and may be an alternative in patients who are elderly and have poor ECOG PS.

ABSTRACT Although gastric cancer is a frequent cancer type, disseminated intravascular coagulation is a very rare but serious complication of this disease. We report a 65-year-old man who complained of weight loss, nausea and vomiting, fatigue and dyspnoea for three days. He was diagnosed as having advanced gastric cancer complicated with disseminated intravascular coagulation, which was successfully treated with mFOLFOX chemotherapy regimen. After one cycle of mFOLFOX therapy, thrombocytopenia was improved and serum lactate dehydrogenase levels decreased. Remarkable remission was seen. After 12 cycles of chemotherapy, remarkable remission was seen in the primary tumour and multiple metastatic bone lesions.

It has been reported that, compared with simple increased nuchal translucency, fetal cases with septated cystic hygroma (CH) are more likely to face perinatal handicaps. However, pediatric outcomes and proper prenatal counseling for this anomaly have not yet been truly defined. We performed this study to determine pregnancy and pediatric outcomes of fetuses with septated CH. We searched records for cases with septated CH and collected data for structural abnormalities, karyotype analysis, and pregnancy outcomes. Fetuses born with septated CH were also evaluated for their pediatric outcomes. Sixty-nine fetuses with septated CH were enrolled in the study. Results showed that chromosomal abnormalities were present in 28 fetuses (40.6%), and the most common aneuploidy was Turner syndrome (n=14, 20.3%); 16 (23.2%) of the remaining cases, in which aneuploidy was not found, had coexistent structural malformations; 25 (36.2%) cases had normal karyotype and morphology. The total number of live births and infants with unfavorable neurologic follow-up were 13 (18.8%) and 2 (2.9%), respectively. Septated CH is associated with poor perinatal outcomes; therefore, karyotype analysis and ultrasonographic anomaly screening should be performed as initial steps, and expectant management should be offered to couples with euploid fetuses that have normal morphology.